Vasoactive Intestinal Peptide • Immune, Vascular & Circadian Signaling
VIP is a 28-amino-acid peptide hormone produced throughout the body, especially in the gut, pancreas, and central nervous system. It is best known in peptide circles for neuroimmune signaling, vasodilation, circadian rhythm regulation, gut barrier support, and CIRS-focused nasal spray protocols.
Vasoactive Intestinal Peptide, usually shortened to VIP, is a naturally occurring 28-amino-acid peptide hormone. Despite the name, VIP is not limited to the intestines. It has broad activity across blood vessels, the immune system, the nervous system, the gut, the pancreas, circadian rhythm biology, and multiple organ systems.
VIP acts through VPAC1 and VPAC2 receptors, which are G protein-coupled receptors found throughout the body. When VIP binds to these receptors, it increases cyclic AMP signaling and activates downstream pathways involved in inflammation control, tissue repair, vascular relaxation, and neuroendocrine communication.
In functional medicine, VIP is most commonly discussed in the context of Chronic Inflammatory Response Syndrome, or CIRS, where low VIP levels are considered one contributor to persistent inflammation, chemical sensitivity, fatigue, brain fog, and multi-system dysfunction.
VIP acts through VPAC1 and VPAC2 receptors, which are G protein-coupled receptors found throughout the body. When VIP binds to these receptors, it increases cyclic AMP signaling and activates downstream pathways involved in inflammation control, tissue repair, vascular relaxation, and neuroendocrine communication.
VIP sits at the intersection of the nervous, endocrine, immune, vascular, and gut systems. It does not simply suppress immune activity; it appears to help rebalance inflammatory signaling by reducing pro-inflammatory cytokines while supporting anti-inflammatory pathways.
VIP has the strongest human discussion around CIRS and pulmonary arterial hypertension research, while broader inflammatory, autoimmune, gut, and neuroprotective claims rely more heavily on mechanistic, animal, in vitro, or early clinical data.
VIP nasal spray is positioned as the final step in the Shoemaker CIRS protocol after exposure, MARCoNS, and other prerequisites have been addressed. Reported outcomes include improvements in symptoms, inflammatory markers, pulmonary pressure, hormones, and brain imaging findings.
VIP is associated with reduced TNF-alpha, IL-6, IL-12, and Th17 signaling, while increasing IL-10 and supporting regulatory T-cell activity. This makes it relevant to chronic inflammatory and autoimmune research contexts.
CIRS reports frequently focus on improved brain fog and cognitive function. VIP also has neuroprotective and circadian rhythm roles that may influence sleep quality and cognitive performance.
VIP relaxes smooth muscle in blood vessels and has been studied in pulmonary arterial hypertension, where inhaled VIP was associated with improved pulmonary pressure and physical capacity in a small open-label study.
VIP supports intestinal epithelial health, gut barrier integrity, water and ion balance, and immune signaling in the gut. These effects are relevant because gut barrier dysfunction is common in chronic inflammatory states.
Low VIP levels are discussed in relation to multiple chemical sensitivity. Patient reports describe reduced environmental reactivity after VIP when the broader CIRS protocol context has been addressed.
Sign in or create a free account to view this content.
Our reported diluent preference is 50% sterile, preservative-free 0.9% saline and 50% bacteriostatic 0.9% sodium chloride. The bacteriostatic component contains a preservative. Use a suitable metered bottle and clean handling.
The example contains 5mg VIP in 10mL final liquid volume, using equal parts of the two diluents: 5mL sterile saline and 5mL bacteriostatic sodium chloride. This gives 500mcg/mL.
At a measured 0.1mL per spray, 500mcg/mL delivers 50mcg per spray. Check the bottle specification and actual output; another pump volume changes the amount per spray.
Keep refrigerated and protected from light according to the formulation instructions. Record the prep date in your research journal.
VIP is not usually described as an acute “feel it immediately” peptide. Timelines are mostly derived from CIRS treatment communities and published Shoemaker protocol outcomes.
Some users report improved energy, reduced brain fog, better sleep, or nasal irritation. Others report temporary worsening if prerequisites were not fully met.
Fatigue reduction, cognitive improvement, and sleep-quality changes may become more noticeable for responders.
Clinical reports describe progressive changes in inflammatory markers, hormone normalization, chemical sensitivity, and brain imaging findings over longer treatment windows.
VIP levels and symptoms may drift if underlying inflammatory triggers remain. Some users require maintenance dosing, while others discontinue after a full course.
VIP is not a random add-on in the CIRS framework. Remove exposure, complete prerequisite steps, then evaluate VIP in the sequence used by the published protocol.
Sequential CIRS tools. Bile-acid binders are used earlier to reduce biotoxin burden; VIP is introduced later after prerequisite steps are complete.
Sequence, not a same-time stack. Active MARCoNS was an exclusion criterion in the published VIP study and is addressed before VIP in the protocol.
Inflammation and gut context. KPV is discussed for localized inflammatory and barrier support, while VIP has broader neuroimmune signaling. Controlled combination data are absent.
Distinct immune pathways. This pairing appears in complex immune-recovery protocols, but direct synergy and optimal sequencing have not been established.
VIP was generally well tolerated in the CIRS-focused reports and small pulmonary hypertension study discussed in the source material, but safety data for chronic, unsupervised, or non-protocol use remains limited.
VIP is one of the more polarizing but quietly effective peptides in the community right now.
Users who respond well report rapid improvements in gut motility, reduced brain fog, better sleep architecture, and noticeable anti-inflammatory effects—especially those dealing with IBS, mold/CIRS, or chronic systemic inflammation. Some call it a game-changer for “feeling human again” when nothing else worked. The vasodilatory and neuroprotective angles also get praise in long-COVID and neuroinflammation circles.
End of the day it’s a solid niche performer with strong anecdotal upside for gut-brain-immune issues, but results are highly individual. Not a daily longevity staple for everyone—best used in short cycles or targeted protocols rather than year-round.
Peptide Protocols
Send us a message and we’ll reply to the email address you provide.